Table 5 Published studies of a dose-intense regimen of capecitabine and oxaliplatin
Trial | n | Chemotherapy | Relative dose intensity* | Overall response (%) | PFS (months) | Gd 3/4 diarrhoea (%) | ||
|---|---|---|---|---|---|---|---|---|
Ox | Cape | |||||||
This trial | ||||||||
_________ | q2w | Oxali 85 mg/m2 | ||||||
19 | Cape 1750 mg/m2 BDd1-7 | 98% | 131% | 47.1% | 6.9 | 31.6% | ||
30 | Cape 1500 mg/m2 BD d1-7 | 98% | 113% | 26.9% | 8.9 | 23.3% | ||
Bevac 5 mg/kg | ||||||||
Phase II trials | ||||||||
Scheithauer [11] | 89 | q2w | Oxali 85 mg/m2 | 98% | 131% | 54.5% | 10.5 | 9% |
Cape 1750 mg/m2 BDd1-7 | ||||||||
vs. | ||||||||
q3w | Oxali 130 mg/m2 | 42.2% | 6 | 12% | ||||
Cape 1000 mg/m2 BD d1-14 | ||||||||
Fedele [19] | 47** | q2w | Oxali 100 mg/m2 | 115% | 75% | 51% | - | 4.3% |
Cape 1000 mg/m2BD d1-7 | ||||||||
Yuan [20] | 23** | q2w | Oxali 85 mg/m2 | 98% | N/A | 61% | - | 26% |
Cape 2500 mg BD d1-7 | ||||||||
Cetux 250 or 500 mg/m2 | ||||||||
Lembersky [21] | q2w | Oxali 85 mg/m2 | 38% | 10 | 18% | |||
11*** | Cape 1250 mg/m2BDd1-7 | 98% | 94% | |||||
29 | Cape 1500 mg/m2 BDd1-7 | 98% | 113% | |||||
Bevac 5 mg/kg | ||||||||
Phase III trials | ||||||||
Hurwitz [17] | 435 | q2w | Oxali 85 mg/m2 | 98% | 113% | 21.7% | 8.4 | 29% |
Cape 1500 mg/m2 BD d1-7 | ||||||||
Bevac 5 mg/kg | ||||||||
vs. | ||||||||
q3w | Oxali 130 mg/m2 | 29.4% | 9.7 | 24% | ||||
Cape 850 mg/m2 BD d1-7 | ||||||||
Bevac 5 mg/kg | ||||||||
Tournigand [22] | 200 | q2w | Oxali 100 mg/m2 | 115% | 94% | - | - | 21% |
Cape 1250 mg/m2BD d1-7 | - | - | ||||||
Bevac 5 mg/kg | ||||||||
vs. | ||||||||
q2w | Oxali 100 mg/m2 | 5% | ||||||
LV 400 mg/m2 | ||||||||
5FU 2400 mg/m2 ci 46 hrs | ||||||||
Bevac 5 mg/kg | ||||||||